Axokine Obesity Trial Setback Weighs Down Regeneron On Wall Street
Executive Summary
Regeneron will explore ways to fine-tune its investigational obesity agent Axokine to increase the percentage of patients that do not develop antibodies to the protein, CEO Leonard Schleifer, MD/PhD, said
You may also be interested in...
Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal
Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin
Sanofi Chews The Fat: Rimonabant Anti-Obesity NDA To Be Filed By 2005
Sanofi-Synthelabo expects to file an NDA for rimonabant in obesity by the first quarter of 2005, Exec VP-Scientific Affairs Gerard Le Fur told analysts during a business review in London Sept. 2
Aventis/Regeneron VEGF Colorectal Cancer Indication Part Of $500 Mil. Deal
Aventis and Regeneron are pursuing a colorectal indication for Regeneron's vascular endothelial growth factor trap after seeing positive results from Genentech's Phase III VEGF inhibitor Avastin